The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

28 Aug 2015 15:31

RNS Number : 5121X
Fastnet Oil & Gas PLC
28 August 2015
 

28 August 2015

 

Fastnet Oil & Gas plc

("Fastnet" or the "Company")

Result of General Meeting, change of name and resignation of a Director

 

Fastnet (AIM: FAST, ESM: FOI), announces that at its General Meeting held earlier today at the Conrad London St James, 22-28 Broadway, London SW1H 0BH, the ordinary resolution approving the Investing Policy, along with the special resolution approving the change of name to Fastnet Equity plc, were duly passed. The voting in respect of each resolution was as follows:

 

Resolution

Number of votes for the resolution1

For

(%)1, 2

Number of votes against the resolution

Against

(%)2

Number of votes withheld3

To approve the Investing Policy

65,852,686

99.92

51,090

0.08

4,664,393

that the Company's name be changed to Fastnet Equity plc

65,854,751

99.93

49,025

0.07

4,664,393

 

Notes:

1. Proxy appointments totalling 192,873 shares gave discretion to the Chairman of the General Meeting and have been included in the "For" total of the appropriate resolution.

2. The number of shares in issue at 6.00 p.m. on 26 August 2015 was 345,369,071.

3. A vote "Withheld" is not a vote in law and is not counted in the calculation of the proportion of the votes "For" and "Against" a resolution.

 

Change of name

Dealings under the name "Fastnet Equity plc" are expected to commence at 8.00 am on Tuesday 1 September 2015. On change of the Company's name the Company's website will be www.fastnetequity.com.

 

Directorate change

As set out in the shareholder circular, following approval of the Proposals at today's General Meeting, Carol Law has today resigned as a director of the Company. Carol will continue as a consultant to the Company as she serves out her three month notice period.

 

Further announcements on the appointment of additional directors with life science experience will be made in due course.

 

Capitalised but undefined terms shall have the meaning given to them in the definitions appearing in the circular.

Cathal Friel, Non-Executive Chairman of Fastnet, commented:

"The Board is grateful for the support of the overwhelming majority of Shareholders, many of whom have suffered from the malaise in the oil industry as have the Board as significant Shareholders. The Board will work tirelessly to source Shareholder accretive deals for the Company in the healthcare sector and looks forward to updating shareholders on progress in the months ahead.

In terms of the Company's Celtic Sea Assets and 3D seismic survey data the Board will continue to examine all options to secure value for Shareholders. Options under consideration include spinning the Celtic Sea Assets into a stand-alone entity. This would enable any value creating opportunities from Celtic Sea Assets to benefit our existing Shareholders who would become shareholders in the newco."

 

For further information please contact:

Fastnet Oil & Gas plc

+353 (1) 644 0007

Cathal Friel, Non-Executive Chairman

Shore Capital

+44 (0) 20 7408 4090

Nomad

Bidhi Bhoma, Edward Mansfield

Corporate Broking

Jerry Keen

Davy

+353 (1) 679 6363

(ESM Adviser & Joint Broker)

John Frain, Anthony Farrell

Camarco

+44 (0) 20 3757 4980

Billy Clegg, Georgia Mann

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROMPKFDNQBKDDFB
Date   Source Headline
4th Mar 202112:00 pmRNSAmryt Announces Record FY 2020 Results
25th Feb 20217:00 amRNSAmryt Supports Global Rare Disease Day 2021
24th Feb 20217:00 amGNWAmryt to Announce Q4 and FY 2020 Results on Thursday March 4, 2021
10th Feb 20217:00 amRNSAmryt to Present at SVB Leerink Conference
4th Feb 20217:00 amGNWAmryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel
20th Jan 20217:00 amGNWAmryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
6th Jan 20217:00 amRNSAmryt to present at H.C Wainwright Conference
23rd Dec 20207:00 amGNWAmryt Granted Orphan Drug Designation by the FDA for AP103
17th Dec 20207:00 amGNWAmryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
11th Dec 202010:00 amGNWHolding(s) in Company
9th Dec 20202:45 pmGNWHolding(s) in Company
9th Dec 20207:00 amGNWAmryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
8th Dec 20207:00 amGNWAmryt Announces $40m Private Placement with Leading Biotech Investors
5th Nov 202012:00 pmGNWAmryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
29th Oct 20207:00 amGNWAMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA
19th Oct 20207:00 amGNWAmryt and Swixx Sign Distribution Deal for Lojuxta
14th Oct 20207:00 amRNSAMRYT TO ANNOUNCE Q3 RESULTS ON NOVEMBER 5, 2020
14th Oct 20207:00 amGNWNotice of Results
12th Oct 202011:00 amGNWHolding(s) in Company
9th Oct 20207:00 amGNWVirtual Analyst & Investor Event - Tuesday November 3, 2020
8th Oct 20207:00 amGNWAMRYT TO PRESENT EASE TRIAL DATA BY LATE-BREAKING PRESENTATION AT EADV ON OCTOBER 31, 2020
1st Oct 20207:00 amGNWExercise of Options and Total Voting Rights
30th Sep 202012:30 pmGNWHolding(s) in Company
23rd Sep 20207:00 amRNSAMRYT SUPPORTS GLOBAL FH AWARENESS DAY
21st Sep 202011:00 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
15th Sep 20207:00 amRNSPOSITIVE OPINION ON AP103 ORPHAN DRUG DESIGNATION
9th Sep 20202:05 pmRNSSecond Price Monitoring Extn
9th Sep 20202:00 pmRNSPrice Monitoring Extension
9th Sep 20207:00 amRNSPOSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB
11th Aug 202011:09 amRNSCANCELLATION OF ADMISSION TO EURONEXT GROWTH
7th Aug 20207:00 amRNSAMRYT PRESENTING AT CANACCORD GENUITY CONFERENCE
6th Aug 202012:00 pmRNSAMRYT ANNOUNCES Q2 2020 RESULTS
29th Jul 20202:30 pmRNSResult of AGM
29th Jul 20207:00 amRNSAMRYT HOSTING KOL CALL ON EB DISEASE LANDSCAPE
20th Jul 20207:00 amRNSAMRYT TO ANNOUNCE Q2 RESULTS ON AUGUST 6, 2020
15th Jul 20208:00 amRNSEuronext Growth Dublin Notice
10th Jul 20207:00 amRNSExercise of Warrants & Issue of Ordinary Shares
8th Jul 20203:09 pmRNSAMRYT LISTED ON NASDAQ & CEO TO RING CLOSING BELL
30th Jun 20207:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
24th Jun 20207:00 amRNSForm F-1 publicly filed for impending US listing
4th Jun 20202:20 pmRNSDirector/PDMR Shareholding
3rd Jun 202011:30 amRNSDirector/PDMR Shareholding
3rd Jun 20207:00 amRNSAMRYT & SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA
11th May 20207:00 amRNSQ1 2020 RESULTS
11th May 20207:00 amRNSFY 2019 RESULTS
7th May 20209:00 amRNSNotice of Results
7th May 20207:00 amRNSFILSUVEZ® CONFIRMED AS GLOBAL BRAND NAME FOR AP101
23rd Apr 20207:00 amRNSEASE CLINICAL STUDY UPDATE
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20207:00 amRNSMarket Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.